Bloomlife

High risk pregnancies are clinically indicated for weekly antepartum fetal monitoring (fetal non-stress tests) starting in the 3rd trimester until delivery. Today such monitoring is only available in a clinical environment (doctor's office, outpatient clinics, L&D triage). Weekly trips are not only time consuming and inconvenient for patients, but require significant clinical overhead (room, staff, equipment).

Bloomlife improves access and convenience to this widely used screening test through our prenatal wearable saving patients time and money and improving the quality of care.

Doctors prescribe Bloomlife. We onboard patients and support data capture from home following a clinically defined schedule. Maternal and fetal data are securely transmitted to clinicians for review and interpretation with seamless integration into clinical workflows.

Patients, OBGYNs, Midwives, Nurse Practitioners

Current antepartum fetal monitoring requires weekly trips to the clinic which is time consuming and inconvenient. For women in underserved communities difficulty accessing care can lead to poor adherence to screening guidelines.

By shifting antepartum fetal monitoring to the home, Bloomlife saves patients time and money, increases adherence to screening guidelines, and frees up valuable clinical resources.